BioSig Technologies Inc. Announces Proposed Public Offering
BioSig Technologies (NASDAQ: BSGM), following its merger with Streamex Exchange Corporation, has announced plans for an underwritten public offering of common stock and pre-funded warrants. The company intends to use the proceeds to purchase gold bullion, working capital, and general corporate purposes.
Clear Street and Needham & Company will serve as joint book-running managers for the offering, which will be conducted under an effective S-3 shelf registration. The final size, timing, and terms of the offering remain subject to market conditions.
BioSig Technologies (NASDAQ: BSGM), a seguito della fusione con Streamex Exchange Corporation, ha annunciato l'intenzione di effettuare un'offerta pubblica sottoscritta di azioni ordinarie e warrant prefinanziati. La societ脿 prevede di impiegare i proventi per l'acquisto di lingotti d'oro, per il capitale circolante e per finalit脿 societarie generali.
Clear Street e Needham & Company agiranno come joint book-running managers dell'offerta, che sar脿 condotta nell'ambito di una registrazione S-3 'shelf' efficace. La dimensione finale, i tempi e i termini dell'offerta restano soggetti alle condizioni di mercato.
BioSig Technologies (NASDAQ: BSGM), tras su fusi贸n con Streamex Exchange Corporation, ha anunciado planes para una oferta p煤blica suscrita de acciones ordinarias y warrants prefinanciados. La compa帽铆a prev茅 destinar los fondos a la compra de lingotes de oro, al capital de trabajo y a prop贸sitos corporativos generales.
Clear Street y Needham & Company actuar谩n como joint book-running managers de la oferta, que se llevar谩 a cabo en el marco de un registro S-3 'shelf' vigente. El tama帽o final, el calendario y los t茅rminos de la oferta estar谩n sujetos a las condiciones del mercado.
BioSig Technologies (NASDAQ: BSGM)電� Streamex Exchange Corporation瓿检潣 頃╇硲 鞚错泟 氤错喌欤� 氚� 靹犽偐 鞗岆煱韸胳棎 雽�頃� 鞚胳垬 瓿惦(鞏鸽崝霛检澊韯� 順曧儨)毳� 瓿勴殟頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 臁半嫭 鞛愱笀鞚� 旮堦创 毵れ瀰, 鞖挫爠鞛愲掣 氚� 鞚茧皹 旮办梾 氇╈爜鞐� 靷毄頃� 鞓堨爼鞛呺媹雼�.
Clear Street鞕� Needham & Company電� 瓿惦鞚� 瓿惦彊 攵侂煬雼� 毵る媹鞝�搿� 頇滊彊頃� 鞓堨爼鞚措┌, 頃措嫻 瓿惦電� 鞙犿毃頃� S-3 'shelf' 霌彪鞐� 霐半澕 歆勴枆霅╇媹雼�. 瓿惦鞚� 斓滌 攴滊, 鞁滉赴 氚� 臁瓣贝鞚� 鞁滌灔 靸來櫓鞐� 霐半澕 雼澕歆� 靾� 鞛堨姷雼堧嫟.
BioSig Technologies (NASDAQ: BSGM), suite 脿 sa fusion avec Streamex Exchange Corporation, a annonc茅 son intention de proc茅der 脿 une offre publique garantie d'actions ordinaires et de warrants pr茅financ茅s. La soci茅t茅 pr茅voit d'utiliser le produit pour l'achat de lingots d'or, pour le fonds de roulement et 脿 des fins g茅n茅rales de l'entreprise.
Clear Street et Needham & Company agiront en tant que co-gestionnaires principaux de l'offre, qui sera r茅alis茅e dans le cadre d'un enregistrement S-3 'shelf' effectif. La taille finale, le calendrier et les modalit茅s de l'offre resteront soumis aux conditions du march茅.
BioSig Technologies (NASDAQ: BSGM) hat nach dem Zusammenschluss mit Streamex Exchange Corporation Pl盲ne f眉r ein unterzeichnetes 枚ffentliches Angebot von Stammaktien und vorab bezahlten Warrants angek眉ndigt. Das Unternehmen beabsichtigt, die Erl枚se f眉r den Kauf von Goldbarren, als Betriebskapital und f眉r allgemeine Unternehmenszwecke zu verwenden.
Clear Street und Needham & Company werden als gemeinsame Bookrunning-Manager f眉r das Angebot fungieren, das unter einer wirksamen S-3-Shelf-Registrierung durchgef眉hrt wird. Die endg眉ltige Gr枚脽e, der Zeitpunkt und die Konditionen des Angebots h盲ngen von den Marktbedingungen ab.
- None.
- Potential dilution for existing shareholders through new share issuance
- Uncertainty regarding the offering's size and terms
- Use of proceeds primarily for gold bullion purchase rather than direct business operations
Insights
BioSig's proposed share offering signals potential dilution while planning to use proceeds for gold bullion purchases and operations.
BioSig Technologies has announced an underwritten public offering of common stock (or pre-funded warrants), though without specifying the size or pricing. This move comes after the company's recent merger with Streamex Exchange Corporation. The offering structure suggests potential dilution for existing shareholders, as new shares will be introduced to the market.
What's particularly notable is the company's stated intention to use proceeds to purchase gold bullion as part of its investment policy, alongside working capital and general corporate purposes. This unusual allocation strategy for a public offering merits attention, as technology companies typically direct offering proceeds toward R&D, market expansion, or debt reduction.
The announcement includes Clear Street and Needham & Company as joint book-running managers, indicating professional financial backing. However, the company explicitly acknowledges market condition uncertainties with no guarantees regarding timing, size, or terms of the offering. This cautious language suggests potential flexibility in how the offering may ultimately be structured.
The offering is being conducted under an existing shelf registration (Form S-3) that was declared effective in December 2024, providing the regulatory framework for this capital raise. This shelf registration approach gives BioSig flexibility to issue securities over time under pre-approved documentation.
Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (鈥淏ioSig鈥� or the 鈥淐ompany鈥�) which recently merged with Streamex Exchange Corporation (鈥淪treamex鈥�) (NASDAQ: BSGM) today announced its intention to offer shares of common stock (or pre-funded warrants in lieu thereof) through an underwritten public offering. All of the shares of common stock (or pre-funded warrants in lieu thereof) are being offered by the Company. The completion of the offering remains subject to market conditions, with no assurance regarding its timing, size, or terms. The Company intends to use the net proceeds from the offering to purchase gold bullion in accordance with its investment policy, for working capital and for general corporate purposes.
Clear Street and Needham & Company, are acting as joint book-running managers of the offering.
The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-276298) declared effective by the Securities and Exchange Commission (the 鈥淪EC鈥�) on December 17, 2024. A preliminary prospectus supplement relating to the offering will be filed with the SEC, together with an accompanying base prospectus. The securities may be offered only by means of a written prospectus forming a part of the effective registration statement. Copies of the preliminary prospectus supplement relating to the offering, together with the accompanying base prospectus, may be obtained, when available, from the SEC鈥檚 website at聽, from Clear Street 聽, Attention: Syndicate, 4 World Trade Center 150 Greenwich St Floor 46 New York, NY 10007, or by email at聽, and Needham & Company, 250 Park Avenue, 10th Floor, New York, NY 10177, Attn: Prospectus Department, or by telephone at (800) 903-3268
Before investing in this offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying base prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying base prospectus, which provide more information about the Company and the offering.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein. BioSig will not, and has been advised by the joint book-running managers that they and their affiliates will not, sell any of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Streamex
Streamex is a RWA and gold tokenization company building Institutional grade infrastructure to bring the gold market on chain, enabled by a gold denominated treasury and tokenization technology powering the gold market of tomorrow.聽 Streamex is a wholly owned subsidiary of BioSig Technologies, Inc.
About BioSig Technologies
BioSig Technologies, Inc. is a medical device technology company with an advanced digital signal processing technology platform, the PURE EP鈩� Platform that delivers insights to electrophysiologists for ablation treatments of cardiovascular arrhythmias.
The PURE EP鈩� Platform enables electrophysiologists to acquire raw signal data in real-time鈥攁bsent of unnecessary noise or interference鈥攖o maximize procedural success and minimize unnecessary inefficiencies. As physician advocates, we believe that the ability to maintain the integrity of intracardiac signals with precision and clarity without driving up procedural costs has never been more pertinent.
Forward Looking Statements
This press release may contain "forward-looking statements" -- that is, statements related to future, not past events, plans, and prospects. In this context, forward-looking statements may address matters such as our expected future business and financial performance, and often contain words such as "guidance," "prospects," "expects," "anticipates," "intends," "plans," "believes," "seeks," "should," or "will." Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Forward-looking statements include, but are not limited to, statements regarding the Company's anticipated public offering, including the completion of the public offering on the anticipated terms, if at all, and other statements that are not historical facts. Particular uncertainties that could adversely or positively affect our future results include: we may not have sufficient resources to fund our business and may need to issue debt or equity to obtain additional funding; risks involved in properly managing complex projects; risks relating to our ability to continue to implement our strategy, including having sufficient financial resources to carry out that strategy; 聽risks relating to whether we will be able to realize the benefits of the acquisition of Streamex; risks relating to whether shareholder approval of the acquisition of Streamex will be obtained; risks relating to whether we will be able to maintain compliance with Nasdaq鈥檚 listing criteria in connection with the acquisition of Streamex; and other risks and uncertainties disclosed in our filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2024. These uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. We do not undertake to update our forward-looking statements.
Contacts Press & Investor Relations: Ele Kauderer [email protected] Henry McPhie CEO of BioSig, Co-Founder of Streamex [email protected] https://x.com/streamex
FAQ
What is the purpose of BioSig Technologies (NASDAQ: BSGM) public offering in August 2025?
Who are the underwriters for BSGM's 2025 public offering?
What securities is BioSig (BSGM) offering in this public offering?
How can investors access BioSig's (BSGM) offering prospectus?
When was BioSig's (BSGM) shelf registration statement declared effective?
